Comparison
SkQ1 vs SS-31
SkQ1: oral, nanomolar mito-antioxidant. SS-31: injectable, peptide-based mito-rescue.
SkQ1
Mitochondria-Targeted Antioxidant
SS-31
Mitochondrial-Targeted Peptide
Effectiveness Profile
At a Glance
| SkQ1 | SS-31 | |
|---|---|---|
| Type | Longevity | Longevity |
| Legal status | Research | Research |
| Half-life | Not formally characterized in humans; mitochondrial residence is prolonged via membrane-potential trapping, supporting once-daily dosing | 2–3.5 hours (plasma); tissue retention much longer |
| Preferred route | Oral | SubQ |
| Dose frequency | once-daily | once-daily |
| Beginner dose | 125–250 mcg | 1–2 mg |
| Intermediate dose | 250–250 mcg | 3–5 mg |
| Advanced dose | 250–500 mcg | 5–10 mg |
| Cycle length | 12–52 wks | 4–12 wks |
| Bioavailability | — | 80% |
| Time to peak | — | 1h |
| Active duration | 24h | 24h |
| Storage | Capsules: room temperature, dry, protected from light. Visomitin drops: 2–8°C refrigerated, room temperature once opened (use within 30 days). | Lyophilized: -20°C long-term, 2–8°C short-term. Reconstituted: 2–8°C, stable ~30 days. |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
SkQ1 wins for oral ease of use, proven safety at longevity-class doses, and strongest data in ophthalmic (dry eye) human trials. Most cost-effective for daily, long-term protocols and uniquely addresses mitochondrial lipid peroxidation.
SS-31 wins for potency as a mitochondrial rescue agent — rapid effects in ATP generation and ETC coupling, direct binding to cardiolipin, and efficacy where acute mitochondrial dysfunction or energy output is the goal. Acute, high-impact results for muscle work and recovery, especially at full clinical dosing (40mg SC).
Pick A or B?
Pick SkQ1 if:
- The goal is long-term mitochondrial health, longevity, and oxidative stress reduction in a low-maintenance daily protocol.
- Oral or ophthalmic administration is preferred (no injectables; stacking for dry eye or isotretinoin protocols).
- Budget or sourcing reliability is the priority (stable oral formulations available).
- Synergy with NAD+ boosters, low-dose rapamycin, and classic longevity stacks is part of the design.
Pick SS-31 if:
- The use case is acute mitochondrial rescue: masters-age lifters, overtraining recovery, or post-insult fatigue.
- Rapid improvement in muscle work capacity or ATPmax is desired (e.g., around events or heavy cycles).
- Injection protocols are not a barrier, and sourcing high-purity peptide is possible.
- Budget allows for near-clinical dosing (10–40mg/day) for visible effects.
